Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion

Nanomedicine. 2021 Jun:34:102366. doi: 10.1016/j.nano.2021.102366. Epub 2021 Feb 5.

Abstract

Intravenous administration of lipid-based nanodrugs can cause hypersensitivity, also known as infusion reactions (IRs), that can be attenuated by slow infusion in adult patients. We studied the role of infusion rate and complement (C) activation in IRs in pediatric patients treated with Abelcet, and also in anesthetized rats. IRs were observed in 6 out of 10 (60%) patients who received Abelcet infusion in 4 h or less, while no patients who received the infusion in 6 h showed C activation or IRs. The rat model indicated an inverse relationship between infusion speed and Abelcet-induced hypotension, taken as an experimental endpoint of IRs, while the rise of C3a in blood, an index of C activation, directly correlated with hypotension. The results suggest that pediatric patients are more prone to produce IRs, and that the optimal infusion time of Abelcet may be much longer than the presently recommended 2 h.

Keywords: Adverse drug effects; CARPA; Complement; Fungal infections; Liposomes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / adverse effects*
  • Animals
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / adverse effects*
  • Child
  • Complement Activation
  • Complement C3a / metabolism*
  • Drug Hypersensitivity*
  • Humans
  • Infusions, Intravenous
  • Male
  • Rats
  • Rats, Wistar
  • Time Factors

Substances

  • Antifungal Agents
  • liposomal amphotericin B
  • Amphotericin B
  • Complement C3a